Chronische Herzinsuffizienz und Depression

Herrmann‐Lingen, Christoph

doi:10.1007/s00108-018-0405-6

Cited by 9 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Depression is prevalent in approximately 20% of patients with HF (ranging from 11% in NYHA class I to 42% in NYHA class IV). Depression is independently related to increased morbidity and mortality 108 as well as to substantially reduced QoL 109 and moderately reduced exercise capacity. Clinical severity of HF as assessed by cardiac function parameters is assumed to interact with depression in a bidirectional way, leading to a vicious circle 110 .…”

Section: Co‐morbidities Of Heart Failurementioning

confidence: 99%

“…individual or group psychotherapy mainly addressing dysfunctional thoughts and related behaviours, significantly improves QoL in depressed HF patients by 0.3 standard deviations 118 . However, QoL is typically reduced by more than 1 standard deviation in depressed vs. non‐depressed HF patients 109 . Additional treatments are therefore needed.…”

Section: Co‐morbidities Of Heart Failurementioning

confidence: 99%

See 1 more Smart Citation

Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials

Haehling

Arzt

Doehner

et al. 2020

European J of Heart Fail

View full text Add to dashboard Cite

Endpoints of large‐scale trials in chronic heart failure have mostly been defined to evaluate treatments with regard to hospitalizations and mortality. However, patients with heart failure are also affected by very severe reductions in exercise capacity and quality of life. We aimed to evaluate the effects of heart failure treatments on these endpoints using available evidence from randomized trials. Interventions with evidence for improvements in exercise capacity include physical exercise, intravenous iron supplementation in patients with iron deficiency, and – with less certainty – testosterone in highly selected patients. Erythropoiesis‐stimulating agents have been reported to improve exercise capacity in anaemic patients with heart failure. Sinus rhythm may have some advantage when compared with atrial fibrillation, particularly in patients undergoing pulmonary vein isolation. Studies assessing treatments for heart failure co‐morbidities such as sleep‐disordered breathing, diabetes mellitus, chronic kidney disease and depression have reported improvements of exercise capacity and quality of life; however, the available data are limited and not always consistent. The available evidence for positive effects of pharmacologic interventions using angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, beta‐blockers, and mineralocorticoid receptor antagonists on exercise capacity and quality of life is limited. Studies with ivabradine and with sacubitril/valsartan suggest beneficial effects at improving quality of life; however, the evidence base is limited in particular for exercise capacity. The data for heart failure with preserved ejection fraction are even less positive, only sacubitril/valsartan and spironolactone have shown some effectiveness at improving quality of life. In conclusion, the evidence for state‐of‐the‐art heart failure treatments with regard to exercise capacity and quality of life is limited and appears not robust enough to permit recommendations for heart failure. The treatment of co‐morbidities may be important for these patient‐related outcomes. Additional studies on functional capacity and quality of life in heart failure are required.

show abstract

Section: Co‐morbidities Of Heart Failurementioning

confidence: 99%

Section: Co‐morbidities Of Heart Failurementioning

confidence: 99%

Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials

Haehling

Arzt

Doehner

et al. 2020

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…[ 1 ] Chronic heart failure (CHF) is a clinical syndrome caused by the fact that the heart cannot discharge enough blood to satisfy the body's metabolism under normal venous return and heart filling pressure. [ 2 ] Many factors can result in CHF, mainly including myocardial infarction, hypertension, diabetes, obesity, valvular heart disease, viral myocarditis, and metabolic syndrome. [ 1 , 3 ]…”

Section: Introductionmentioning

confidence: 99%

The clinical application value of the plasma copeptin level in the assessment of heart failure with reduced left ventricular ejection fraction

Liu

et al. 2018

Medicine

View full text Add to dashboard Cite

This study aimed to evaluate the clinical applicability of the plasma copeptin level to assess heart failure with reduced left ventricular ejection fraction (HFrEF).One hundred thirty-one patients with HFrEF, 127 patients with heart failure with preserved left ventricular ejection fraction (HFpEF), and 119 healthy candidates were involved. The basic data and examination results of patients were collected. The heart function of the patients with HFrEF and HFpEF were graded on the basis of the criteria of New York Heart Association (NYHA) classification. The plasma copeptin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels were tested using enzyme-linked immunosorbent assays (ELISAs).The copeptin and NT-proBNP levels were higher in the HFrEF group than in the HFpEF group. The copeptin and NT-proBNP values increased as the NYHA grade increased in the patients with HFrEF. However, for the patients with HFpEF, the copeptin levels did not change markedly as the NYHA grade increased. The copeptin levels were positively correlated with the NT-proBNP levels in the patients with HFrEF; however, there was no correlation between the copeptin and NT-proBNP values in the patients with HFpEF.Copeptin is involved in the process of progression in patients with HFrEF and the copeptin values might be useful for HFrEF prediction and assessment in the clinic.

show abstract

“…CHF can lead to alterations in myocardial structure and function, resulting in impaired ventricular function, decreased ventricular ejection capacity, prolonged disease course, and recurrent episodes; it is a leading cause of death in patients with cardiovascular disease [ 8 , 9 ]. The incidence of CHF in Chinese adults is approximately 0.9%, and it continues to gradually increase [ 10 ]. The pathogenesis of CHF is complex, and no treatment is available for this disease.…”

Section: Discussionmentioning

confidence: 99%

Simvastatin Combined with Resistance Training Improves Outcomes in Patients with Chronic Heart Failure by Modulating Mitochondrial Membrane Potential and the Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling Pathways

Wang

Yan

Wen

et al. 2022

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Background. Chronic heart failure (CHF) is the end stage of cardiac disease with a 5-year mortality rate reaching 50%. Simvastatin is an antioxidant with lipid-lowering effects, which is commonly used to treat CHF. Resistance training is a nondrug treatment for CHF and exerts a positive effect on both the myocardial structure and function. Objective. This study is aimed at exploring the effects and outcomes of simvastatin combined with resistance training on the mitochondrial membrane potential (MMP) of peripheral blood lymphocytes and the Janus kinase/signal transducer and activator of the transcription 3 (JAK/STAT3) signaling pathway in patients with CHF. Methods. One hundred and eleven patients with CHF were allocated to the control group (CNG) ( n = 55 ) and intervention group (IG) ( n = 56 ) using the random number table method. The CNG received simvastatin treatment only, whereas the IG received simvastatin treatment plus resistance training. Treatment efficacy, diastolic interventricular septal thickness (IVST), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVDD), MMP fluorescence intensity, JAK mRNA and STAT3 mRNA relative expression levels, serum C-reactive protein (CRP), galectin-3, interleukin-6 (IL-6), N-terminal–probrain natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and heart-type fatty acid-binding protein (H-FABP) levels were compared in both groups. Results. After 6 months of treatment, diastolic IVST, LVDD, and serum levels of CRP, galectin-3, IL-6, NT-proBNP, hs-cTnT, and H-FABP decreased in both groups and were lower in the IG than in the CNG ( P < 0.05 ), whereas LVEF, JAK and STAT3 mRNA relative expression levels, and MMP fluorescence intensity of peripheral blood lymphocytes were higher in the IG than in the CNG ( P < 0.05 ). Conclusion. Simvastatin combined with resistance training improves heart function and reduces myocardial damage as well as the occurrence of adverse cardiac events compared with simvastatin alone. The mechanism may be related to the increase of expression of MMP, JAK, and STAT3, the regulation of MMP and JAK/STAT3 signaling pathways in peripheral lymphocytes, the alleviation of mitochondrial damage, and the inhibition of inflammatory response.

show abstract

Chronische Herzinsuffizienz und Depression

Cited by 9 publications

References 23 publications

Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials

Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials

The clinical application value of the plasma copeptin level in the assessment of heart failure with reduced left ventricular ejection fraction

Simvastatin Combined with Resistance Training Improves Outcomes in Patients with Chronic Heart Failure by Modulating Mitochondrial Membrane Potential and the Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling Pathways

Contact Info

Product

Resources

About